CAR T-Cell farfadowa da yarda

Yuli 2021: A watan Yuni 2014, KITE Biotechnology Company, mai ma'aikata 19 kawai, an jera shi akan NASDAQ a Amurka, kuma ya ɗauki dalar Amurka miliyan 130 a rana ɗaya! Bayan watanni biyu kacal, Juno Biotechnology yana da ma’aikata kasa da 20 Kamfanin ya sanar da cewa ya samu nasarar tara dalar Amurka miliyan 130 a dunkule guda, don haka Juno ya tara sama da miliyan 300 a shekara guda! Waɗannan ƙananan kamfanoni guda biyu ba su da kuɗin shiga kuma ba su da jerin magunguna, to me ya sa suke shahara da masu zuba jari kuma ana aika musu kuɗi? Domin sun ƙware wata fasaha mai suna CAR-T cell therapy, fasahar da za ta iya magance cutar daji! A zamanin yau, an ambaci sanannen CAR-T, kusan kowa ya san wannan, Immunotherapy ya shiga aikace-aikacen asibiti a hukumance.

FDA ta amince da hanyoyin kwantar da CAR-T guda biyu

Currently, two CAR T-cell therapies approved by the FDA, Yescarta and Kymriah, are used to treat leukemia and linzoma, bi da bi.

Waɗannan jiyya an nuna su don haifar da mahimman martani - har ma da marasa lafiya masu fama da cutar kansa waɗanda suka rayu kawai 'yan watanni za a iya kawar da su gaba ɗaya, kuma a wasu lokuta suna ba da ƙarfi da ƙarfi na watanni ko ma shekaru.

Misali, Emily, yarinya mai cutar sankarar bargo, an samu nasarar warkewarta ta hanyar kwayar cutar CAR-T tsawon shekaru 7. Ta kuma zama mai magana da yawun wannan maganin almara kuma an rubuta ta a cikin tarihi.

Mu'ujiza na CAR T-Cell far

EMILY - LEUKEMIA GIRL 2019

Dr. CARL JUNE – MAI HARAWA NA T-CELL THERAPY

Menene CAR T Cell far?

Wannan maganin ya ware kwayoyin T na rigakafi daga marasa lafiya, kuma injiniyan kwayar halittar wadannan kwayoyin a cikin vitro, yana loda su da “chimeric antigen receptors” (CARs) wanda ke gane kwayar cutar kanjamau. Bayan haka, waɗannan ƙwayoyin da aka gyara sun faɗaɗa faɗaɗa a cikin dakin gwaje-gwaje kafin a sake dawo dasu cikin mai haƙuri. A can, sun kasance kamar runduna mai cikakken horo waɗanda aka wadata su da sabbin makamai don kai farmaki ba kakkautawa kan ƙwayoyin kansa.

Bottleneck na CAR-T fasaha a cikin m ƙari

However, the reason why it is effective in hematoma is because the tumo cells of hematoma have an ancestral target-CD19 (only stored in tumor cells but not in normal cells), we can easily rely on this target Lead CAR-T cells to find cancer cells and eliminate cancer. A third CAR T-cell therapy targeting an antigen called BCMA is expected to be approved for Multi myeloma (Bluebird) later this year. But there are not so obvious targets in solid tumors that exist only in cancer cells and not in normal cells.

Sabili da haka, ƙwayoyin CAR-T ba su da tasiri a asibiti wajen magance kumburi mai ƙarfi. Medicalungiyar likitanci koyaushe tana fatan ƙwayoyin CAR T na iya haɓaka sababbin ƙayyadaddun maƙasudi don ƙarin ƙwayoyin cuta masu ƙarfi.

Gano ci gaba a cikin CAR-T a kan tsauraran ƙwayoyi

At present, with the change of CAR-T algebra, CAR-T has obvious improvements in proliferation and cytokine release. This technology has finally broken the ice, and more and more clinical trials have begun to try to use CAR-T for solid tumors. Treatment, patients with advanced solid tumors ushered in a warm spring!

Abubuwan da aka saba amfani dasu na antigen sun hada da:

Mesothelin, used to treat karinda, pancreatic cancer, ovarian cancer, lung cancer; CEA, used to treat lung cancer, colon cancer, stomach cancer, breast cancer and pancreatic cancer; MUC-1, used to treat liver cancer, lung cancer , Pancreatic cancer, colon cancer, gastric cancer; GPC3, for the treatment of liver cancer; EGFRvII, for the treatment of gliomas, head and neck tumors; B7-H3, for the treatment of Ewing’s sarcoma, rhabdomyosarcoma, nephroblastoma, nerves Blastoma and medulloblastoma and brain stem tumors (DIPG), which are particularly difficult to treat;

PSMA, used for prostate ciwon daji, da sauransu;

Claudin 18.2, used for gastric cancer, ciwon cizon sauro, Da dai sauransu

01 Mesothelin CAR-T

Mesothelin is a cell surface glycoprotein that is highly expressed in various tumors, such as malignant pleural mesothelioma, pancreatic cancer, ciwon daji na ovarian and some lung cancers, and is lowly expressed on the surface of normal pleura, peritoneum and pericardium. CAR-T cells against mesothelin have potential antitumor effects.

The latest results of mesothelin CAR-T therapy published by the University of Pennsylvania at the American Society of Clinical Oncology in 2019 show that a total of 6 patients with refractory metastatic pancreatic duct adenocarcinoma were successfully enrolled, and all patients have received 2 or more Multiple treatments. These patients were infused with mesothelin CAR T cells 3 times a week for a total of 9 doses. The results showed that there were 2 patients with stable disease, and their progression-free survival time was 3.8 months and 5.4 months.

Sabili da haka, wannan farfadowa na ilimin zamani yana aiki da ilimin halittu a cikin marasa lafiya da cutar sankarar mahaifa, kuma wannan binciken har yanzu yana cikin gwajin asibiti (NCT03323944).

02 - B7-H3 "Ciwon kansar" CAR-T

Tawagar Farfesa Majzner daga Kwalejin Kiwon Lafiya ta Stanford ta haɓaka sabon ƙarni na maganin CAR-T don ciwace-ciwace. Wannan na musamman CAR T-Cell far ana yaba shi a matsayin ɗayan mahimman hanyoyin kwantar da hankali saboda yana ƙaddamar da B7-H3, babban matakin antigen da ke cikin ƙwayoyin cuta masu yawa, gami da wasu cututtukan yara.

They screened 388 children’s tumors for testing. The results showed that B7-H3 was present in 84% of the samples (tumor cells). B7-H3 content was very high in 70% of the samples. These include Ewing’s sarcoma, rhabdomyosarcoma, nephroblastoma, neuroblastoma and medulloblastoma, as well as brain stem tumors (DIPG) that are particularly difficult to treat.

Bayan haka, Farfesa Majzner da tawagarsa sun kafa sabon ƙarni na ƙwayoyin CAR-T-B7-H3 CAR-T ta hanyar fasahar gyara jigilar mutane.

Nan da nan bayan haka, masu binciken basu iya jiran fara gwajin akan beraye ba. Sun dasa ƙwayoyin cututtukan mutum zuwa cikin beraye don ƙirƙirar samfuran linzamin mahaifa da yawa na kansar yara. Wadannan nau'ikan linzamin kwamfuta an basu B7-H3 CAR T-Cell far da CD-19 CAR-T ƙungiyar sarrafawa, bi da bi.

Kowa ya birgeshi! Farfesa Majzner ya ce: "Yanzu haka kumburin ya ɓace."

03, claudin18.2 CAR-T

A cikin shekaru biyun da suka gabata, ciwukan ciwuka a cikin kasarmu sun cimma nasarorin da duniya ta san su, kuma ciwan farko na farko a duniya CAR-T far an ƙaddamar da niyya Claudin 18.2.

Claudin18.2 (CLDN18.2) furotin ne na takamaiman ƙwayar ciki kuma ana ɗaukarsa makasudin maganin cutar kansa da sauran nau'o'in cutar kansa. A kan wannan, masu binciken Sinawa suka ƙaddamar da ƙwayoyin CAR-T na farko a duniya kan Claudin 18.2.

A taron shekara-shekara na ASCO na 2019, sabunta bayanai na asibiti na kwayoyin CAR-Claudin 18.2 T don cututtukan ciki / na ciki sun nuna cewa an yi amfani da ƙwayoyin claudin 18.2 CAR T da aka yi niyya don magance sharuɗɗan 12 na adenocarcinoma na metastatic (shari'o'in 7 na cututtukan ciki da na 5 na pancreatic ciwon daji) Wani mummunan haɗari, mutuwa mai alaƙa da magani, ko mummunan lahani.

Daga cikin abubuwa kimantawa 11:

1 harka (adenocarcinoma na ciki) gaba daya an sauke;

Abubuwa 3 (adenocarcinoma na ciki

Shari'o'in 2 na adenocarcinoma na pancreatic, harka 1) gafarar sashi;

Shari'a 5 sun kasance barga;

Shari'a 2 ta ci gaba;

Matsakaicin matakin mayar da martani shine 33.3%.

Bugu da ƙari, ƙwayoyin CAR-Claudin 18.2 T don cikakken bincike kan kansar ciki sun nuna cewa ƙwayoyin CAR-T da aka yi niyya ga Claudin 18.2 na iya kawar da ciwace-ciwacen ciki a cikin ƙirar linzamin kwamfuta ba tare da an kashe su ba.

The good news is that this trial has been pioneered by the Department of Gastroenterology and Oncology at Peking University Cancer Hospital, which is famous for ciwan ciki in China, to evaluate autologous humanized anti-claudin 18.2 chimeric antigen receptor T cells in advanced solid tumors. Safety and efficacy. Entry criteria (partial)

1. Shekaru 18 zuwa 75, mace ko namiji;

2. Batutuwa da ke da alaƙa da ƙwaƙƙwaran ciwace-ciwacen ƙwayoyin cuta (watau babban ciwan ciki, ciwon sankarar mahaifa, da ciwon sankara) waɗanda suka gaza ingantaccen magani;

3.Claudin 18.2 IHC tabo mai kyau;

Rayuwar da ba'a tsammani> makonni 4;

CAR T-Cell hanyoyin kwantar da hankali kan daukar ma'aikata na asibiti

Baya ga ci gaban da aka ambata na ci gaban binciken asibiti, manyan asibitocin cikin gida a halin yanzu suna gudanar da bincike na CAR-T na asibiti akan ciwace-ciwace daban-daban.

Bukatun haƙuri: Shekaru 18-80 da haihuwa, ana tsammanin zasu rayu na aƙalla watanni 6 (daga nazarin farko na kayan aiki har zuwa kammala magani yana ɗaukar watanni 5-6), gabaɗaya cikin kyakkyawan yanayi, zasu iya rayuwa da kansu.

Tsarin aikace-aikace don daukar ma'aikata CAT T-Cell

1. Bita na farko na kayan: Rahoton ilimin cututtuka, bayanan gwajin hoto a cikin wata daya, rahoton aikin hanta da koda na baya-bayan nan, taƙaitaccen bayani na kwanan nan da aka gabatar zuwa Cibiyar Kiwon Lafiya ta CancerFax;

2. Tattaunawa ta fuska da fuska: Mai haƙuri da kansa ya kawo duk kayan shari'ar zuwa asibitin gwaji na gwaji na fuskantar fuska-da-fuska (rahoton rahoto, fitowar taƙaitaccen bayani, fim ɗin rahoton hoto);

3. Immuno histochemical ganewa: gano tumor cell surface antigens EGFR, MUC1 da mesothelin, daya daga cikin abin da yake da karfi tabbatacce (high magana) na iya amfani da CAR T-Cell far.

Kafin zuwan maganin tantanin halitta, ƙaƙƙarfan ciwace-ciwace, gami da ci-gaban adenocarcinoma na ciki da ciwon daji na pancreatic, yawanci ana yi musu aikin tiyata da aikin rediyo da chemotherapy. Abubuwan da ke faruwa na adenocarcinoma na ciki sun kai kashi 95 cikin dari na cututtuka na ciki, kuma ciwon daji na pancreatic shine ciwon daji na yau da kullum. Ciwon daji tare da digiri mafi girma, lokacin rayuwa na tsaka-tsaki da kuma shekarun rayuwa na shekaru 5 sun yi ƙasa da sauran ciwace-ciwacen daji, wanda aka sani da "sarkin ciwon daji".

Koyaya, yawancin marasa lafiya suna da sake dawowa na gida ko ƙwayar cuta bayan aiki. Bugu da ƙari, wannan nau'in mummunan ƙwayar cuta ba shi da damuwa ga radiotherapy da chemotherapy. Sabili da haka, gwargwadon tsarin ilimin yau da kullun, tasirin jiyya ba shi da kyau, kuma hangen nesa ba shi da kyau. Zuwan rigakafin rigakafi zai kawo ƙarin bege da al'ajibai na rayuwa na dogon lokaci ga ƙwararrun marasa lafiya.

Mun yi imanin cewa bayan gabatar da cikakken tsarin kula da garkuwar jiki, kasar za ta bude kofa ga maganin rigakafin salula don amfanar da yawa daga masu fama da cutar kansa, kuma maganin rigakafi na kasarmu zai kasance a matakin duniya.

Kuna so karanta: CAR T-Cell far a China

Tambayoyi game da CAR T-Cell far

Shin akwai wadatar ƙwayar ƙwayar Car-T? Abin da cutar kansa yafi kulawa

A CAR-T cell immunotherapy has been amince by the US FDA for the treatment of leukemia and lymphoma. Duk da haka, ba a yarda da maganin ciwace-ciwacen ƙwayoyi ba kuma a halin yanzu yana cikin gwaji na asibiti

Shin ƙwayoyin Car-T na iya magance kansar ciki?

Amsa CAR-T don ciwon daji na ciki a halin yanzu yana fuskantar gwajin asibiti a cikin Cancer na Beijing. Ana buƙatar marasa lafiya suyi amfani da sassan nama a cikin shekara guda zuwa ƙungiyar gwaji don takamaiman gano manufa. Idan sakamakon gwajin ya tabbata, to

Shin akwai gwajin asibiti na ƙwayoyin Car-T don cutar kansa?

A Akwai gwaji na cikin gida na CAR-T don cutar kansa, wanda aka gudanar a asibitin Peking University Cancer Hospital. Ana buƙatar marasa lafiya su sami sassan ƙwayoyin cuta a cikin shekara guda don tantance takamaiman manufa. A halin yanzu an sanya marasa lafiya

Shin masu cutar kansar hanta za su iya shiga cikin gwajin asibiti na CAR-T?

Amsa According to your main complaint; the clinical application of CAR-T immunotherapy for solid tumors of ciwon daji is not approved. The principle of CAR-T is to extract immune cells, and then use in vitro culture

Aiwatar da CAR T-Cell far

Aiwatar Yanzu